Business Context and Reporting Period
Company: Context Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2025
Reporting Period: Event date February 27, 2025; Signed February 28, 2025
Business Context: The Company is an emerging growth company incorporated in Delaware, with common stock (Symbol: CNTX) listed on The Nasdaq Stock Market.
Key Financial Metrics
This filing is a current report regarding a listing compliance issue and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Delisting Notice: On February 27, 2025, the Company received a Notification Letter from Nasdaq stating it is not in compliance with Listing Rule 5550(a)(2) (Minimum Bid Price Rule).
Reason for Non-Compliance: The common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
Immediate Effect: The Notification Letter has no immediate effect on the listing or trading of the Company's common stock.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has an initial 180-calendar-day period (until August 26, 2025) to regain compliance.
- Regaining Compliance: Compliance is achieved if the bid price closes at $1.00 or more for 10 consecutive business days before the deadline.
- Future Options: If compliance is not met by August 26, 2025, the Company may be eligible for an additional 180-day grace period.
- Management Action: The Company intends to actively monitor the closing bid price and evaluate available options to regain compliance.
- Risks: There is no assurance the Company will regain compliance during the initial period, secure a second grace period, or maintain other Nasdaq listing requirements.
Investor Verification Checklist
- Verify the current closing bid price of CNTX stock relative to the $1.00 threshold.
- Monitor the Company's progress toward achieving 10 consecutive days of closing prices at or above $1.00 before August 26, 2025.
- Review future filings for any announcements regarding reverse stock splits or other capital structure changes intended to address the bid price deficiency.
- Check for any subsequent communications from Nasdaq regarding the status of the compliance period.